Calvisi Diego F, Simile Maria M, Ladu Sara, Pellegrino Rossella, De Murtas Valentina, Pinna Federico, Tomasi Maria L, Frau Maddalena, Virdis Patrizia, De Miglio Maria R, Muroni Maria R, Pascale Rosa M, Feo Francesco
Division of Experimental Pathology and Oncology, Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
Int J Cancer. 2007 Dec 1;121(11):2410-20. doi: 10.1002/ijc.22940.
Mounting evidence underlines the role of genomic hypomethylation in the generation of genomic instability (GI) and tumorigenesis, but whether DNA hypomethylation is required for hepatocellular carcinoma (HCC) development and progression remains unclear. We investigated the correlation between GI and DNA methylation, and influence of methionine metabolism deregulation on these parameters and hepatocarcinogenesis in c-Myc and c-Myc/Tgf-alpha transgenic mice and human HCCs. S-adenosyl-L-methionine/S-adenosylhomocysteine ratio and liver-specific methionine adenosyltransferase (MatI/III) progressively decreased in dysplastic and neoplastic liver lesions developed in c-Myc transgenic mice and in human HCC with better (HCCB) and poorer (HCCP) prognosis (based on patient's survival length). Deregulation of these parameters resulted in a rise of global DNA hypomethylation both in c-Myc and human liver lesions, positively correlated with GI levels in mice and humans, and inversely correlated with the length of survival of HCC patients. No changes in MATI/III and DNA methylation occurred in c-Myc/Tgf-alpha lesions and in a small human HCC subgroup with intermediate prognosis, where a proliferative activity similar to that of c-Myc HCC and HCCB was associated with low apoptosis. Upregulation of genes involved in polyamine synthesis, methionine salvage and downregulation of polyamine negative regulator OAZ1, was highest in c-Myc/Tgf-alpha HCCs and HCCP. Our results indicate that alterations in the activity of MAT/I/III, and extent of DNA hypomethylation and GI are prognostic markers for human HCC. However, a small human HCC subgroup, as c-Myc/Tgf-alpha tumors, may develop in the absence of alterations in DNA methylation.
越来越多的证据表明基因组低甲基化在基因组不稳定(GI)的产生和肿瘤发生中起作用,但DNA低甲基化是否是肝细胞癌(HCC)发生发展所必需的仍不清楚。我们研究了GI与DNA甲基化之间的相关性,以及蛋氨酸代谢失调对c-Myc和c-Myc/Tgf-α转基因小鼠及人类HCC中这些参数和肝癌发生的影响。在c-Myc转基因小鼠以及预后较好(HCCB)和较差(HCCP)(基于患者生存时间)的人类HCC中,发育异常和肿瘤性肝损伤中S-腺苷-L-蛋氨酸/S-腺苷同型半胱氨酸比值以及肝脏特异性蛋氨酸腺苷转移酶(MatI/III)逐渐降低。这些参数的失调导致c-Myc和人类肝脏损伤中整体DNA低甲基化增加,与小鼠和人类的GI水平呈正相关,与HCC患者的生存时间呈负相关。在c-Myc/Tgf-α损伤以及一小部分预后中等的人类HCC亚组中,MATI/III和DNA甲基化没有变化,这些亚组中与c-Myc HCC和HCCB相似的增殖活性与低凋亡相关。参与多胺合成、蛋氨酸补救的基因上调以及多胺负调节因子OAZ1的下调在c-Myc/Tgf-α HCC和HCCP中最为明显。我们的结果表明,MAT/I/III活性、DNA低甲基化程度和GI的改变是人类HCC的预后标志物。然而,一小部分人类HCC亚组,如c-Myc/Tgf-α肿瘤,可能在DNA甲基化无改变的情况下发生。